The DOI matches its Crossref record; 174 of the 174 references it cites were found in a registry or an index.
Ras in Cancer and Developmental Diseases
Open accessAbstract
Somatic, gain-of-function mutations in ras genes were the first specific genetic alterations identified in human cancer about 3 decades ago. Studies during the last quarter century have characterized the Ras proteins as essential components of signaling networks controlling cellular proliferation, differentiation, or survival. The oncogenic mutations of the H-ras, N-ras, or K-ras genes frequently found in human tumors are known to throw off balance the normal outcome of those signaling pathways, thus leading to tumor development. Oncogenic mutations in a number of other upstream or downstream components of Ras signaling pathways (including membrane RTKs or cytosolic kinases) have been detected more recently in association with a variety of cancers. Interestingly, the oncogenic Ras mutations and the mutations in other components of Ras/MAPK signaling pathways appear to be mutually exclusive events in most tumors, indicating that deregulation of Ras-dependent signaling is the essential requirement for tumorigenesis. In contrast to sporadic tumors, separate studies have identified germline mutations in Ras and various other components of Ras signaling pathways that occur in specific association with a number of different familial, developmental syndromes frequently sharing common phenotypic cardiofaciocutaneous features. Finally, even without being a causative force, defective Ras signaling has been cited as a contributing factor to many other human illnesses, including diabetes and immunological and inflammatory disorders. We aim this review at summarizing and updating current knowledge on the contribution of Ras mutations and altered Ras signaling to development of various tumoral and nontumoral pathologies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Estimates of the cancer incidence and mortality in Europe in 2006
Ferlay, J., Autier, P., Boniol, M., Heanue, M., Colombet, M., & Boyle, P. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl498 · Cited by 4,036
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Estimates of cancer incidence and mortality in Europe in 2008
Ferlay, J., Parkin, D. M., & Steliarova-Foucher, E. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.014 · Cited by 2,319
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., & Perucho, M. (1988) · Cell · doi:10.1016/0092-8674(88)90571-5 · Cited by 2,114
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
Tartaglia, M., Mehler, E. L., Goldberg, R., Zampino, G., Brunner, H. G., Kremer, H., van der Burgt, I., Crosby, A. H., Ion, A., Jeffery, S., et al. (2001) · Nature Genetics · doi:10.1038/ng772 · Cited by 1,733
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
Genetics and biology of pancreatic ductal adenocarcinoma
Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N., & DePinho, R. A. (2006) · Genes & Development · doi:10.1101/gad.1415606 · Cited by 1,577
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C., Whittaker, S., Nourry, A., Niculescu-Duvas, I., Dhomen, N., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,465
Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S. L., Herbst, R. S., Ince, W. L., Jänne, P. A., Januario, T., Johnson, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.857 · Cited by 1,461
Lièvre, A., Bachet, J.-B., Boige, V., Cayre, A., Le Corre, D., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,444
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179
BRAF and RAS mutations in human lung cancer and melanoma.
Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048
Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene
Parada, L. F., Tabin, C. J., Shih, C., & Weinberg, R. A. (1982) · Nature · doi:10.1038/297474a0 · Cited by 944
K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors
Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., Bishop, W. R., & Pai, J.-K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14459 · Cited by 884
Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma
Singer, G., Oldt, R., Cohen, Y., Wang, B. G., Sidransky, D., Kurman, R. J., & Shih, I.-M. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.6.484 · Cited by 854
Blocking Oncogenic Ras Signaling for Cancer Therapy
Adjei, A. A. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1062 · Cited by 831
Der, C. J., Krontiris, T. G., & Cooper, G. M. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.11.3637 · Cited by 800
Van Cutsem, E., van de Velde, H., Karasek, P., Oettle, H., Vervenne, W. L., Szawlowski, A., Schoffski, P., Post, S., Verslype, C., Neumann, H., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.112 · Cited by 786
The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation
Tidyman, W. E., & Rauen, K. A. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.04.001 · Cited by 780
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
Kiyoi, H., Naoe, T., Nakano, Y., Yokota, S., Minami, S., Miyawaki, S., Asou, N., Kuriyama, K., Jinnai, I., Shimazaki, C., et al. (1999) · PubMed · doi:10.1182/blood.v93.9.3074 · Cited by 757
Eerola, I., Boon, L. M., Mulliken, J. B., Burrows, P. E., Dompmartin, A., Watanabe, S., Vanwijck, R., & Vikkula, M. (2003) · The American Journal of Human Genetics · doi:10.1086/379793 · Cited by 756
Germline KRAS mutations cause Noonan syndrome
Schubbert, S., Zenker, M., Rowe, S. L., Böll, S., Klein, C., Bollag, G., van der Burgt, I., Musante, L., Kalscheuer, V., Wehner, L.-E., et al. (2006) · Nature Genetics · doi:10.1038/ng1748 · Cited by 730
Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy
Pandit, B., Sarkozy, A., Pennacchio, L. A., Carta, C., Oishi, K., Martinelli, S., Pogna, E. A., Schackwitz, W., Ustaszewska, A., Landstrom, A., et al. (2007) · Nature Genetics · doi:10.1038/ng2073 · Cited by 698
Germline mutations in HRAS proto-oncogene cause Costello syndrome
Aoki, Y., Niihori, T., Kawame, H., Kurosawa, K., Ohashi, H., Tanaka, Y., Filocamo, M., Kato, K., Suzuki, Y., Kure, S., et al. (2005) · Nature Genetics · doi:10.1038/ng1641 · Cited by 679
Hruban, R. H., van Mansfeld, A. D. M., Offerhaus, G. J. A., van Weering, D. H. J., Allison, D. C., Goodman, S. N., Kensler, T. W., Bose, K., Cameron, J. L., & Bos, J. L. (1993) · PubMed Central · Cited by 650
Santos, E., Tronick, S. R., Aaronson, S. A., Pulciani, S., & Barbacid, M. (1982) · Nature · doi:10.1038/298343a0 · Cited by 623
Self-citationGermline gain-of-function mutations in SOS1 cause Noonan syndrome
Roberts, A. E., Araki, T., Swanson, K. D., Montgomery, K. T., Schiripo, T. A., Joshi, V. A., Li, L., Yassin, Y., Tamburino, A. M., Neel, B. G., et al. (2007) · Nature Genetics · doi:10.1038/ng1926 · Cited by 605
Mascaux, C., Iannino, N., Martin, B., Paesmans, M., Berghmans, T., Dusart, M., Haller, A., Lothaire, P., Meert, A.-P., Noel, S., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602258 · Cited by 605
Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome
Niihori, T., Aoki, Y., Narumi, Y., Neri, G., Cavé, H., Verloes, A., Okamoto, N., Hennekam, R. C. M., Gillessen-Kaesbach, G., Wieczorek, D., et al. (2006) · Nature Genetics · doi:10.1038/ng1749 · Cited by 599
Bollag, G., Clapp, D. W., Shih, S., Adler, F., Zhang, Y. Y., Thompson, P., Lange, B. J., Freedman, M. H., McCormick, F., Jacks, T., et al. (1996) · Nature Genetics · doi:10.1038/ng0296-144 · Cited by 589
Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma
Riely, G. J., Kris, M. G., Rosenbaum, D., Marks, J., Li, A., Chitale, D. A., Nafa, K., Riedel, E. R., Hsu, M., Pao, W., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0646 · Cited by 578
Germline Mutations in Genes Within the MAPK Pathway Cause Cardio-facio-cutaneous Syndrome
Rodriguez-Viciana, P., Tetsu, O., Tidyman, W. E., Estep, A. L., Conger, B. A., Cruz, M. S., McCormick, F., & Rauen, K. A. (2006) · Science · doi:10.1126/science.1124642 · Cited by 571
K-ras is an essential gene in the mouse with partial functional overlap with N-ras
Johnson, L., Greenbaum, D., Cichowski, K., Mercer, K., Murphy, E., Schmitt, E., Bronson, R. T., Umanoff, H., Edelmann, W., Kucherlapati, R., et al. (1997) · Genes & Development · doi:10.1101/gad.11.19.2468 · Cited by 545
Mashiyama, S., Kayama, T., Katakura, R., Yoshimoto, T., Murakami, Y., Sekiya, T., & Hayashi, K. (1991) · Biological Aspects of Brain Tumors · doi:10.1007/978-4-431-68150-2_41 · Cited by 535
Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective
Ferner, R. E. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70075-3 · Cited by 511
Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
Montagut, C., Sharma, S. V., Shioda, T., McDermott, U., Ulman, M., Ulkus, L. E., Dias-Santagata, D., Stubbs, H., Lee, D. Y., Singh, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6787 · Cited by 508
Clinical and genetic aspects of neurofibromatosis 1
Jett, K., & Friedman, J. M. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181bf15e3 · Cited by 501
Germline gain-of-function mutations in RAF1 cause Noonan syndrome
Razzaque, M. A., Nishizawa, T., Komoike, Y., Yagi, H., Furutani, M., Amo, R., Kamisago, M., Momma, K., Katayama, H., Nakagawa, M., et al. (2007) · Nature Genetics · doi:10.1038/ng2078 · Cited by 498
Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1–like phenotype
Brems, H., Chmara, M., Sahbatou, M., Denayer, E., Taniguchi, K., Kato, R., Somers, R., Messiaen, L., De Schepper, S., Fryns, J.-P., et al. (2007) · Nature Genetics · doi:10.1038/ng2113 · Cited by 472
Rodenhuis, S., Slebos, R. J. C., Boot, A. J., Evers, S. G., Mooi, W. J., WAGENAAR, S. S., Bodegom, P. C. V., & Bos, J. L. (1988) · PubMed · Cited by 465
Ras oncogenes and their downstream targets
Rajalingam, K., Schreck, R., Rapp, U. R., & Albert, Š. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.01.012 · Cited by 458
Ahrendt, S. A., Decker, P. A., Alawi, E. A., Zhu, Y.-R., Sanchez-Cespedes, M., Yang, S. C., Haasler, G. B., Kajdacsy-Balla, A., Demeure, M. J., & Sidransky, D. (2001) · Cancer · doi:10.1002/1097-0142(20010915)92:6<1525::aid-cncr1478>3.0.co;2-h · Cited by 449
Shannon, K. M., O'Connell, P., Martin, G. A., Paderanga, D., Olson, K., Dinndorf, P., & McCormick, F. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300903 · Cited by 444
Revencu, N., Boon, L. M., Mulliken, J. B., Enjolras, O., Cordisco, M. R., Burrows, P. E., Clapuyt, P., Hammer, F., Dubois, J., Baselga, E., et al. (2008) · Human Mutation · doi:10.1002/humu.20746 · Cited by 435
Cordeddu, V., Di Schiavi, E., Pennacchio, L. A., Ma'ayan, A., Sarkozy, A., Fodale, V., Cecchetti, S., Cardinale, A., Martin, J., Schackwitz, W., et al. (2009) · Nature Genetics · doi:10.1038/ng.425 · Cited by 419
Yuen, S. T., Davies, H. R., Chan, T. L., Ho, J. W. C., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Tsui, W. W., Chan, A. S. Y., et al. (2002) · PubMed · Cited by 404
NF1 Gene and Neurofibromatosis 1
Rasmussen, S. A., & Friedman, J. M. (2000) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010118 · Cited by 401
cDNA cloning of the type 1 neurofibromatosis gene: Complete sequence of the NF1 gene product
Marchuk, D. A., Saulino, A. M., Tavakkol, R., Swaroop, M., Wallace, M. R., Andersen, L. B., Mitchell, A. L., Gutmann, D. H., Boguski, M., & Collins, F. S. (1991) · Genomics · doi:10.1016/0888-7543(91)90017-9 · Cited by 389
Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer
Vaughn, C. P., ZoBell, S. D., Furtado, L. V., Baker, C. L., & Samowitz, W. S. (2011) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20854 · Cited by 377
Caldas, C., Hahn, S. A., Hruban, R. H., Redston, M. S., Yeo, C. J., & Kern, S. E. (1994) · PubMed · Cited by 377
Molecular genetics of neurofibromatosis type 1 (NF1).
Shen, M. H., Harper, P. S., & Upadhyaya, M. (1996) · Journal of Medical Genetics · doi:10.1136/jmg.33.1.2 · Cited by 377
ras Mutations Are Associated With Aggressive Tumor Phenotypes and Poor Prognosis in Thyroid Cancer
Garcia-Rostan, G., Zhao, H., Camp, R. L., Pollan, M., Herrero, A., Pardo, J., Wu, R., Carcangiu, M. L., Costa, J., & Tallini, G. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.130 · Cited by 368
The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders
Aoki, Y., Niihori, T., Narumi, Y., Kure, S., & Matsubara, Y. (2008) · Human Mutation · doi:10.1002/humu.20748 · Cited by 365
PTPN11 (Shp2) Mutations in LEOPARD Syndrome Have Dominant Negative, Not Activating, Effects
Kontaridis, M. I., Swanson, K. D., David, F. S., Barford, D., & Neel, B. G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513068200 · Cited by 338
Malignancy in Neurofibromatosis Type 1
Korf, B. R. (2000) · The Oncologist · doi:10.1634/theoncologist.5-6-477 · Cited by 328
A restricted spectrum of NRAS mutations causes Noonan syndrome
Cirstea, I. C., Kutsche, K., Dvorsky, R., Gremer, L., Carta, C., Horn, D., Roberts, A. E., Lepri, F., Merbitz-Zahradnik, T., König, R., et al. (2010) · Nature Genetics · doi:10.1038/ng.497 · Cited by 315
Reuter, C. W. M., Morgan, M. A., & Bergmann, L. (2000) · Blood · doi:10.1182/blood.v96.5.1655 · Cited by 300
Esteban, L. M., Vicario-Abejón, C., Fernández-Salguero, P., Fernández-Medarde, A., Swaminathan, N., Yienger, K., Lopez, E., Malumbres, M., McKay, R., Ward, J. M., et al. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1444-1452.2001 · Cited by 298
Self-citationSarkozy, A., Digilio, M. C., & Dallapiccola, B. (2008) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-3-13 · Cited by 293
Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
Janakiraman, M., Vakiani, E., Zeng, Z., Pratilas, C. A., Taylor, B. S., Chitale, D., Halilovic, E., Wilson, M., Huberman, K., Ricarte Filho, J. C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0192 · Cited by 290
Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study
Stiller, C., Chessells, J., & Fitchett, M. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.431 · Cited by 287
Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice.
Kohl, N. E., Wilson, F. R., Mosser, S. D., Giuliani, E., deSolms, S. J., Conner, M. W., Anthony, N. J., Holtz, W. J., Gomez, R. P., & Lee, T. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.19.9141 · Cited by 285
New insight into BRAF mutations in cancer
Dhomen, N., & Marais, R. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.005 · Cited by 278
Development of Farnesyl Transferase Inhibitors: A Review
Appels, N. M. G. M., Beijnen, J. H., & Schellens, J. H. M. (2005) · The Oncologist · doi:10.1634/theoncologist.10-8-565 · Cited by 272
The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma
Conlin, A., Smith, G., Carey, F. A., Wolf, C. R., & Steele, R. J. C. (2005) · Gut · doi:10.1136/gut.2005.066514 · Cited by 261
NRAS mutation causes a human autoimmune lymphoproliferative syndrome
Oliveira, J. B., Bidère, N., Niemela, J. E., Zheng, L., Sakai, K., Nix, C. P., Danner, R. L., Barb, J., Munson, P. J., Puck, J. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702975104 · Cited by 257
Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants
Hocker, T., & Tsao, H. (2007) · Human Mutation · doi:10.1002/humu.20481 · Cited by 257
Nava, C., Hanna, N., Michot, C., Pereira, S., Pouvreau, N., Niihori, T., Aoki, Y., Matsubara, Y., Arveiler, B., Lacombe, D., et al. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2007.050450 · Cited by 256
Molecular pathways of urothelial development and bladder tumorigenesis
Castillo-Martin, M., Domingo-Domenech, J., Karni-Schmidt, O., Matos, T., & Cordon-Cardo, C. (2010) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.04.019 · Cited by 251
Noonan Syndrome: Clinical Aspects and Molecular Pathogenesis
Tartaglia, M., Zampino, G., & Gelb, B. D. (2010) · Molecular Syndromology · doi:10.1159/000276766 · Cited by 246
Protein tyrosine phosphatase SHP-2: A proto-oncogene product that promotes Ras activation
Matozaki, T., Murata, Y., Saito, Y., Okazawa, H., & Ohnishi, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01257.x · Cited by 240
Wu, X., Simpson, J., Hong, J. H., Kim, K.-H., Thavarajah, N. K., Backx, P. H., Neel, B. G., & Araki, T. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44929 · Cited by 234
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
Singh, M., Lima, A., Molina, R., Hamilton, P., Clermont, A. C., Devasthali, V., Thompson, J. D., Cheng, J. H., Bou Reslan, H., Ho, C. C. K., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1640 · Cited by 215
A Mutation in the SOS1 Gene Causes Hereditary Gingival Fibromatosis Type 1
Hart, T. C., Zhang, Y., Gorry, M. C., Hart, P. S., Cooper, M., Marazita, M. L., Marks, J. M., Cortelli, J. R., & Pallos, D. (2002) · The American Journal of Human Genetics · doi:10.1086/339689 · Cited by 209
ras gene Amplification and malignant transformation.
Pulciani, S., Santos, E., Long, L. K., Sorrentino, V, & Barbacid, M. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.10.2836 · Cited by 202
Self-citationNRAS Mutations Are Rare in Colorectal Cancer
Irahara, N., Baba, Y., Nosho, K., Shima, K., Yan, L., Dias-Santagata, D., Iafrate, A. J., Fuchs, C. S., Haigis, K. M., & Ogino, S. (2010) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e3181c93fd1 · Cited by 194
Paquette, R., Landaw, E., Pierre, R., Kahan, J., Lubbert, M., Lazcano, O., Isaac, G., McCormick, F., & Koeffler, H. (1993) · Blood · doi:10.1182/blood.v82.2.590.590 · Cited by 194
Graziano, S. L., Gamble, G. P., Newman, N. B., Abbott, L. Z., Rooney, M., Mookherjee, S., Lamb, M. L., Kohman, L. J., & Poiesz, B. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.668 · Cited by 191
Garassino, M. C., Marabese, M., Rusconi, P., Rulli, E., Martelli, O., Farina, G., Scanni, A., & Broggini, M. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq680 · Cited by 184
Wedén, S., Klemp, M., Gladhaug, I. P., Møller, M., Eriksen, J. A., Gaudernack, G., & Buanes, T. (2011) · International Journal of Cancer · doi:10.1002/ijc.25449 · Cited by 183
Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium
Goebell, P. J., & Knowles, M. A. (2010) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2010.04.003 · Cited by 181
Cohen, S. J., Ho, L., Ranganathan, S., Abbruzzese, J. L., Alpaugh, R. K., Beard, M., Lewis, N. L., McLaughlin, S., Rogatko, A., Perez-Ruixo, J. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.040 · Cited by 174
Nash, G. M., Gimbel, M., Shia, J., Nathanson, D. R., Ndubuisi, M. I., Zeng, Z.-S., Kemeny, N., & Paty, P. B. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0605-3 · Cited by 172
Raymond, F. L., Tarpey, P. S., Edkins, S., Tofts, C., O’Meara, S., Teague, J., Butler, A., Stevens, C., Barthorpe, S., Buck, G., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/513609 · Cited by 172
Cejas, P., López-Gómez, M., Aguayo, C., Madero, R., de Castro, J., Belda-Iniesta, C., Barriuso, J., Moreno, V., Larrauri, J., López, R., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008199 · Cited by 169
Detection of K-ras mutations in lung carcinomas: Relationship to prognosis
(1996) · Lung Cancer · doi:10.1016/s0169-5002(96)80041-9 · Cited by 168
Targeting the RET Pathway in Thyroid Cancer
Wells, S. A., & Santoro, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2742 · Cited by 168
Clinical and biological significance of RAS mutations in multiple myeloma
Chng, W. J., Gonzalez-Paz, N., Price-Troska, T., Jacobus, S., Rajkumar, S. V., Oken, M. M., Kyle, R. A., Henderson, K. J., Van Wier, S., Greipp, P., et al. (2008) · Leukemia · doi:10.1038/leu.2008.142 · Cited by 161
Calvisi, D. F., Ladu, S., Conner, E. A., Seo, D., Hsieh, J.-T., Factor, V. M., & Thorgeirsson, S. S. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.06.036 · Cited by 159
Gremer, L., Merbitz-Zahradnik, T., Dvorsky, R., Cirstea, I. C., Kratz, C. P., Zenker, M., Wittinghofer, A., & Ahmadian, M. R. (2011) · Human Mutation · doi:10.1002/humu.21377 · Cited by 158
Taya, Y., Hosogai, K., Hirohashi, S., Shimosato, Y., Tsuchiya, R., Tsuchida, N., Fushimi, M., Sekiya, T., & Nishimura, S. (1984) · The EMBO Journal · doi:10.1002/j.1460-2075.1984.tb02236.x · Cited by 158
Kawesha, A., Ghaneh, P., Andrén‐Sandberg, Å., Ögraed, D., Skar, R., Dawiskiba, S., Evans, J. D., Campbell, F., Lemoine, N. R., & Neoptolemos, J. P. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001120)89:6<469::aid-ijc1>3.0.co;2-l · Cited by 152
Cawthon, R., O'Connell, P., Buchberg, A. M., Viskochil, D. H., Weiss, R. B., Culver, M., Stevens, J., Jenkins, N. A., Copeland, N. G., & White, R. L. (1990) · Genomics · doi:10.1016/0888-7543(90)90199-5 · Cited by 148
Chen, X., Mitsutake, N., LaPerle, K., Akeno, N., ZANZONICO, P. B., Longo, V. A., Mitsutake, S., Kimura, E. T., Geiger, H., Santos, E., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900343106 · Cited by 147
Self-citationHusgafvel‐Pursiainen, K., Hackman, P., Ridanpää, M., Anttila, S. L., Karjalainen, A., Partanen, T. J., Taikina-aho, O., Heikkilä, L. J., & Vainio, H. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910530213 · Cited by 145
Shih, L.-Y., Huang, C.-F., Wang, P.-N., Jh, W., Lin, T.-L., Dunn, P., & Kuo, M.-C. (2004) · Leukemia · doi:10.1038/sj.leu.2403274 · Cited by 145
Omholt, K., Karsberg, S., Platz, A., Kanter, L., Ringborg, U. K., & Hansson, J. (2002) · PubMed · Cited by 144
Lu, C. S., Soria, J., Tang, X., Xu, X.-C., Wang, L., Mao, L., Lotan, R., Kemp, B. L., Bekele, B. N., Feng, L., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.091 · Cited by 143
Molecular footprints of human lung cancer progression
Yokota, J., & Kohno, T. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb02203.x · Cited by 139
Complications of Radioactive Iodine Treatment of Thyroid Carcinoma
Lee, S. L. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0094 · Cited by 138
Chronic Myeloid Leukemia: A Historical Perspective
Goldman, J. M. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.07.001 · Cited by 137
Ugurel, S., Thirumaran, R. K., Bloethner, S., Gast, A., Sucker, A., Mueller-Berghaus, J., Rittgen, W., Hemminki, K., Becker, J. C., Kumar, R., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000236 · Cited by 134
KRAS mutations predict response to EGFR inhibitors
Raponi, M., Winkler, H. J. S., & Dracopoli, N. C. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.006 · Cited by 130
K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer
Chen, H., Tu, H., Meng, Z. Q., Chen, Z., Wang, P., & Liu, L. M. (2010) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2010.05.014 · Cited by 128
A mouse model for Costello syndrome reveals an Ang II–mediated hypertensive condition
Schuhmacher, A. J., Guerra, C. E., Sauzeau, V., Cañamero, M., Bustelo, X. R., & Barbacid, M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34385 · Cited by 128
Noonan, Costello and cardio–facio–cutaneous syndromes: dysregulation of the Ras–MAPK pathway
Tidyman, W. E., & Rauen, K. A. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000902 · Cited by 127
N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma.
Hara, H., Fulton, N. C., YASHIRO, T., Ito, K., DeGroot, L. J., & Kaplan, E. L. (1994) · PubMed · Cited by 124
Deregulated Ras signaling in developmental disorders: new tricks for an old dog
Schubbert, S., Bollag, G. E., & Shannon, K. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.004 · Cited by 122
Ramírez, J. L., Sarries, C., Castro, P., Roig, B., Queralt, C., Escuín, D., de Aguirre, I., Sánchez, J. M., Manzano, J. L., Vila, M. M., et al. (2003) · Cancer Letters · doi:10.1016/s0304-3835(02)00740-1 · Cited by 121
RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia
Perentesis, J. P., Bhatia, R., Boyle, E., Shao, Y., Shu, X., Steinbuch, M., Sather, H. N., Gaynon, P. S., Kiffmeyer, W. R., Envall-Fox, J., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403272 · Cited by 118
Kitanaka, C. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.5.358 · Cited by 115
Mutant KRAS in aberrant crypt foci (ACF): Initiation of colorectal cancer?
Pretlow, T. P., & Pretlow, T. G. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.06.002 · Cited by 111
Paulsson, K. M., Horvat, A., Strömbeck, B., Nilsson, F., Heldrup, J., Behrendtz, M., Forestier, E., Andersson, A., Fioretos, T., & Johansson, B. (2007) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20502 · Cited by 111
Lüth, H. J., Holzer, M., Gertz, H.-J., & Arendt, T. (2000) · Brain Research · doi:10.1016/s0006-8993(99)02178-2 · Cited by 105
DeMarini, D. M., Landi, S., Tian, D., Hanley, N. M., Li, X., Hu, F., Roop, B. C., Mass, M. J., Keohavong, P., Gao, W., et al. (2001) · PubMed · Cited by 105
Signaling Pathways Activated by Oncogenic Forms of Abl Tyrosine Kinase
Zou, X., & Calame, K. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.26.18141 · Cited by 104
Oishi, K., Zhang, H., Gault, W. J., Wang, C. J., Tan, C. C., Kim, I.-K., Ying, H., Rahman, T., Pica, N., Tartaglia, M., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn336 · Cited by 103
Jorge, A. A. L., Malaquias, A. C., Arnhold, I. J. P., & Mendonca, B. B. (2009) · Hormone Research in Paediatrics · doi:10.1159/000201106 · Cited by 100
Mutant N-ras Induces Myeloproliferative Disorders and Apoptosis in Bone Marrow Repopulated Mice
MacKenzie, K. L., Dolnikov, A., Millington, M., Shounan, Y., & Symonds, G. P. (1999) · Blood · doi:10.1182/blood.v93.6.2043.406k17_2043_2056 · Cited by 99
Nash, G. M., Gimbel, M. I., Cohen, A. M., Zeng, Z., Ndubuisi, M. I., Nathanson, D. R., Ott, J., Barany, F., & Paty, P. B. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0713-0 · Cited by 99
RASA1 mutations may cause hereditary capillary malformations without arteriovenous malformations
Hershkovitz, D., Bercovich, D., Sprecher, E., & Lapidot, M. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08493.x · Cited by 99
Clinical and molecular aspects of RAS related disorders
Denayer, E., de Ravel, T. J. L., & Legius, E. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2007.055772 · Cited by 97
Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins
Kim, J., Reber, H. A., Dry, S., Elashoff, D. A., Chen, S. L., Umetani, N., Kitago, M., Hines, O. J., Kazanjian, K. K., Hiramatsu, S., et al. (2006) · Gut · doi:10.1136/gut.2005.083063 · Cited by 97
Origin and prognostic value of circulating KRAS mutations in lung cancer patients
Gautschi, O. P., Huegli, B., Ziegler, A., Gugger, M., Heighway, J., Ratschiller, D., Mack, P. C., Gumerlock, P. H., Kung, H., Stahel, R. A., et al. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.03.008 · Cited by 95
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)
the Cancer and Leukemia Group B, Gajewski, T. F., Salama, A. K. S., Niedzwiecki, D., Johnson, J. E., Linette, G. P., Bucher, C. J., Blaskovich, M. A., Sebti, S. M., & Haluska, F. G. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-246 · Cited by 94
N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis
Lübbert, M., Mirro, J., Cw, M., Kahan, J., Isaac, G., Kitchingman, G. R., Mertelsmann, R., Herrmann, F., McCormick, F. P., & Koeffler, H. (1990) · Blood · doi:10.1182/blood.v75.5.1163.1163 · Cited by 89
Receptor tyrosine kinases in normal and malignant haematopoiesis
Reilly, J. T. (2003) · Blood Reviews · doi:10.1016/s0268-960x(03)00024-9 · Cited by 87
Dergham, S. T., Dugan, M. C., Kucway, R., Du, W., Kamarauskiene, D. S., Vaitkevicius, V. K., Crissman, J. D., & Sarkar, F. H. (1997) · International Journal of Pancreatology · doi:10.1007/bf02822384 · Cited by 86
Immervoll, H., Hoem, D., Kugarajh, K., Steine, S. J., & Molven, A. (2006) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-006-0191-8 · Cited by 85
High frequency of K-ras mutations in sporadic colorectal adenomas.
McLellan, E. A., Owen, R., Stepniewska, K., Sheffield, J. P., & Lemoine, N. R. (1993) · Gut · doi:10.1136/gut.34.3.392 · Cited by 84
Kipp, B. R., Fritcher, E. G. B., Clayton, A. C., Gores, G. J., Roberts, L. R., Zhang, J., Levy, M. J., & Halling, K. C. (2010) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.100016 · Cited by 83
Martin, N. E., Brunner, T. B., Kiel, K. D., DeLaney, T. F., Regine, W. F., Mohiuddin, M., Rosato, E. F., Haller, D. G., Stevenson, J. P., Smith, D., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0248 · Cited by 83
Hong, D. S., Sebti, S. M., Newman, R. A., Blaskovich, M. A., Ye, L., Gagel, R. F., Moulder, S., Wheler, J. J., Naing, A., Tannir, N. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1241 · Cited by 83
Steinbrunn, T., Stühmer, T., Gattenlöhner, S., Rosenwald, A., Mottok, A., Unzicker, C., Einsele, H., Chatterjee, M., & Bargou, R. C. (2010) · Blood · doi:10.1182/blood-2010-05-284422 · Cited by 82
Perspectives on farnesyl transferase inhibitors in cancer therapy
Mazières, J., Pradines, A., & Favre, G. (2003) · Cancer Letters · doi:10.1016/j.canlet.2003.08.033 · Cited by 79
Novel human pathological mutations
Lewis, P. D. (2006) · Human Genetics · doi:10.1007/s00439-005-0109-6 · Cited by 76
Detection of K-ras gene mutations in non-neoplastic lung tissue and lung cancers
Nelson, M. A., Wymer, J. A., & Clements, N. C. (1996) · Cancer Letters · doi:10.1016/0304-3835(96)04202-4 · Cited by 74
K-rasMutations and Prognosis in Large-Bowel Carcinomas
Andersen, S. N., Løvig, T., Breivik, J., Lund, E., Gaudernack, G., Meling, G., & Rognum, T. O. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709025065 · Cited by 70
A microRNA contribution to aberrant Ras activation in gastric cancer.
Lam, E. K. Y., Wang, X., Shin, V. Y., Zhang, S., Morrison, H., Sun, J. L., Ng, E. K. O., Yu, J. Q., & Jin, H. (2011) · PubMed · Cited by 62
Varying degrees of amplification of the N-ras oncogene in the human breast cancer cell line MCF-7.
Graham, K., Richardson, C. L., Minden, M. D., Trent, J. M., & Buick, R. N. (1985) · PubMed · Cited by 60
Legius syndrome in fourteen families
Denayer, E., Chmara, M., Brems, H., Maat‐Kievit, A., van Bever, Y., van den Ouweland, A. M., van Minkelen, R., de Goede-Bolder, A., Oostenbrink, R., Lakeman, P., et al. (2010) · Human Mutation · doi:10.1002/humu.21404 · Cited by 59
Molecular pathology of differentiated thyroid cancer.
Greco, A., Borrello, M. G., Miranda, C., Degl'Innocenti, D., & Pierotti, M. A. (2009) · PubMed · Cited by 57
The H-ras oncogene product p21 and prognosis in human breast cancer
Watson, D. M., Elton, R. A., Jack, W. J. L., Dixon, J. M., Chetty, U., & Miller, W. R. (1991) · Breast Cancer Research and Treatment · doi:10.1007/bf01806365 · Cited by 57
Saif, M. W., Oettle, H., Vervenne, W. L., Thomas, J. P., Spitzer, G., Visseren‐Grul, C., Enas, N. H., & Richards, D. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181b36264 · Cited by 57
Potential role of sorafenib in the treatment of acute myeloid leukemia
Mori, S., Cortes, J. E., Kantarjian, H. M., Zhang, W., Andreef, M., & Ravandi, F. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802510349 · Cited by 55
Activation of N-ras induced by ultraviolet irradiation in vitro.
van der Lubbe, J. L. M., Rosdorff, H. J. M., Bos, J. L., & van der Eb, A. J. (1988) · PubMed · Cited by 54
Camps, C., Sirera, R., Bremnes, R. M., Blasco, A., Sancho, E., Bayo, P., Safont, M. J., Sánchez, J. J., Tarón, M., & Rosell, R. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.06.007 · Cited by 53
Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using LightCycler
Sasaki, H., Okuda, K., Kawano, O., Endo, K., Yukiue, H., Yokoyama, T., Yano, M., & Fujii, Y. (2007) · Oncology Reports · doi:10.3892/or.18.3.623 · Cited by 52
Deschoolmeester, V., Boeckx, C., Baay, M. F. D., Weyler, J., Wuyts, W. A., Marck, E. V., Peeters, M., Lardon, F., & Vermorken, J. B. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605959 · Cited by 51
A novel N-ras mutation in malignant melanoma is associated with excellent prognosis.
Demunter, A., Ahmadian, M. R., Libbrecht, L. J., Stas, M., Baens, M., Scheffzek, K., Degreef, H. J., Wolf‐Peeters, C. D., & van den Oord, J. J. (2001) · PubMed · Cited by 48
Confino‐Cohen, R., Aharoni, D., Goldberg, A., Gurevitch, I., Buchs, A. E., Weiss, M., Weissgarten, J., & Rapoport, M. J. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.121314 · Cited by 48
Draznin, B., Miles, P. D. G., Kruszynska, Y. T., Olefsky, J. M., Friedman, J. E., Golovchenko, I., Stjernholm, R., Wall, K., Reitman, M. L., Accili, D., et al. (2000) · Endocrinology · doi:10.1210/en.141.4.1310 · Cited by 48
Germ Line Gain of Function with SOS1 Mutation in Hereditary Gingival Fibromatosis
Jang, S.-I., Lee, E. J., Hart, P. S., Ramaswami, M., Pallos, D., & Hart, T. C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701609200 · Cited by 46
A Systems Perspective of Ras Signaling in Cancer
Stites, E. C., & Ravichandran, K. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2753 · Cited by 46
Sathyan, K. M., Nalinakumari, K. R., & Kannan, S. (2007) · Modern Pathology · doi:10.1038/modpathol.3800948 · Cited by 45
Fast simultaneous detection of K-RASmutations in colorectal cancer
Chang, Y., Yeh, K., Chang, T., Chai, C., Lu, H., Hsu, N. C.-H., & Chang, J. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-179 · Cited by 45
NF1 gene loss of heterozygosity and expression analysis in sporadic colon cancer
Čaćev, T., Radosević, S., Spaventi, R., Pavelić, K., & Kapitanović, S. (2005) · Gut · doi:10.1136/gut.2004.053348 · Cited by 45
Johne, A., Roots, I., & Brockmöller, J. (2003) · PubMed · Cited by 39
Benter, I. F., Yousif, M. H. M., Canatan, H., & Akhtar, S. (2005) · Pharmacological Research · doi:10.1016/j.phrs.2005.04.001 · Cited by 37
Transcriptional activation of H- and N-ras oncogenes in human cervical cancer
Mammas, I., Zafiropoulos, A., Koumantakis, E. E., Sifakis, S., & Spandidos, D. A. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.11.040 · Cited by 35
c-Ki-ras amplification in human lung cancer
Heighway, J., & Hasleton, P. S. (1986) · British Journal of Cancer · doi:10.1038/bjc.1986.47 · Cited by 35
Choudhary, S., & Wang, H. R. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0586 · Cited by 33
Activation of K-RAS by co-mutation of codons 19 and 20 is transforming
Naguib, A., Wilson, C. H., Adams, D. J., & Arends, M. J. (2011) · Journal of Molecular Signaling · doi:10.1186/1750-2187-6-2 · Cited by 31
de Melo, M. B., Lorand-Metze, I. G. H., Lima, C. S. P., Saad, S. T. O., & Costa, F. F. (1997) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199709039018 · Cited by 29
Current Status of Imatinib as Frontline Therapy for Chronic Myeloid Leukemia
Marín, D. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.06.003 · Cited by 25
Sorafenib: Rays of Hope in Thyroid Cancer
Duntas, L. H., & Bernardini, R. (2010) · Thyroid · doi:10.1089/thy.2010.0056 · Cited by 20
Kanwar, M., & Kowluru, R. A. (2008) · Microvascular Research · doi:10.1016/j.mvr.2008.04.002 · Cited by 20
MutationView/KMcancerDB: A database for cancer gene mutations
Shimizu, N., Ohtsubo, M., & Minoshima, S. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00405.x · Cited by 19
Administration of Anti-EGFR Therapy: A Practical Review
Khoukaz, T. (2006) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2006.01.012 · Cited by 16
Genetic analysis of KRAS mutation status in metastatic colorectal cancer patients
Závodná, K., Konečný, M., Krivulcik, T., Spanik, S., Behulová, R., Vizvaryova, M., Weismanova, E., Galbavý, Š., & Kausitz, J. (2009) · Neoplasma · doi:10.4149/neo_2009_03_275 · Cited by 12
Hammerhead Ribozymes as Therapeutic Agents for Bladder Cancer
Irie, A., Kashani–Sabet, M., Kj, S., Uchida, Τ., & Baba, S. (2000) · Molecular Urology · doi:10.1089/10915360050138602 · Cited by 5
Cited by
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
Risk Factors and Preventions of Breast Cancer
Sun, Y.-S., Zhao, Z., Yang, Z.-N., Xu, F., Lu, H.-J., Zhu, Z.-Y., Shi, W., Jiang, J., Yao, P.-P., & Zhu, H.-P. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.21635 · Cited by 2,003
A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer
Braicu, C., Buse, M., Busuioc, C., Drula, R., Gulei, D., Raduly, L., Rusu, A., Irimie, A., Atanasov, A. G., Slaby, O., et al. (2019) · Cancers · doi:10.3390/cancers11101618 · Cited by 944
Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone
Behjati, S., Tarpey, P. S., Presneau, N., Scheipl, S., Pillay, N., Van Loo, P., Wedge, D. C., Cooke, S. L., Gundem, G., Davies, H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2814 · Cited by 854
Metadata
- Authors
- Fernandez-Medarde, A., & Santos, E.
- Venue
- Genes & Cancer
- Publisher
- SAGE Publications
- Published
- 2011-03-01
- Volume
- 2
- Issue
- 3
- Pages
- 344-358
- ISSN
- 1947-6019 (ISSN-L)
- 1947-6027
- OpenAlex
- W2143881980
- Cited by
- 897
- References
- 174
- FWCI
- 15.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.